Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Next Previous
Trial Profile

A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO MAPT (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Dementia
  • Focus Adverse reactions
  • Sponsors Arrowhead Pharmaceuticals

Most Recent Events

  • 30 Oct 2025 New trial record
  • 10 Sep 2025 According to Arrowhead Pharmaceuticals media release, the company intends to initiate the Phase 1/2a study following Medsafe clearance and continue expanding its TRiM RNAi platform to multiple tissues including the central nervous system (CNS).
  • 10 Sep 2025 According to an Arrowhead Pharmaceuticals media release, the company has filed a request for regulatory clearance with the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initiate a Phase 1/2a clinical trial of ARO-MAPT, an investigational RNA interference (RNAi) therapeutic for the treatment of Alzheimer's disease and other tauopathies. Pending regulatory approval, the company plans to commence the study shortly.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top